212 related articles for article (PubMed ID: 26915469)
1. Real-world data on eslicarbazepine acetate as add-on to antiepileptic monotherapy.
Holtkamp M; McMurray R; Bagul M; Sousa R; Kockelmann E
Acta Neurol Scand; 2016 Jul; 134(1):76-82. PubMed ID: 26915469
[TBL] [Abstract][Full Text] [Related]
2. [Anticonvulsant add-on therapy with Eslicarbazepine acetate : Results of the EPOS-study in adults in Germany].
Losch FP; Holtkamp M; McMurray R; Lendemans D; Kockelmann E
Nervenarzt; 2016 Oct; 87(10):1094-1099. PubMed ID: 27550387
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures.
Chung S; Sinha SR; Shah A; Stern JM; Cheng H; Jung J; Grinnell T; Blum D
Epilepsy Res; 2019 Jul; 153():59-65. PubMed ID: 30999260
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open-label extension study.
Trinka E; Rocamora R; Chaves J; Moreira J; Ikedo F; Soares-da-Silva P;
Epilepsia; 2020 Oct; 61(10):2129-2141. PubMed ID: 32944934
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.
Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P;
Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424
[TBL] [Abstract][Full Text] [Related]
6. Eslicarbazepine acetate add-on for drug-resistant partial epilepsy.
Chang XC; Yuan H; Wang Y; Xu HQ; Zheng RY
Cochrane Database Syst Rev; 2011 Dec; (12):CD008907. PubMed ID: 22161441
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study.
Toledano R; Jovel CE; Jiménez-Huete A; Bayarri PG; Campos D; Gomariz EL; Giráldez BG; García-Morales I; Falip M; Agredano PM; Palao S; Prior MJAA; Pascual MRQ; Navacerrada FJ; González FJL; Ojeda J; Sáez AA; Bermejo PE; Gil-Nagel A
Epilepsy Behav; 2017 Aug; 73():173-179. PubMed ID: 28641170
[TBL] [Abstract][Full Text] [Related]
8. Euro-Esli: a European audit of real-world use of eslicarbazepine acetate as a treatment for partial-onset seizures.
Villanueva V; Holtkamp M; Delanty N; Rodriguez-Uranga J; McMurray R; Santagueda P
J Neurol; 2017 Nov; 264(11):2232-2248. PubMed ID: 28921040
[TBL] [Abstract][Full Text] [Related]
9. Two-year follow-up with eslicarbazepine acetate: a consecutive, retrospective, observational study.
Correia FD; Freitas J; Magalhães R; Lopes J; Ramalheira J; Lopes-Lima J; Chaves J
Epilepsy Res; 2014 Oct; 108(8):1399-405. PubMed ID: 25060997
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America.
Sperling MR; Harvey J; Grinnell T; Cheng H; Blum D;
Epilepsia; 2015 Apr; 56(4):546-55. PubMed ID: 25689448
[TBL] [Abstract][Full Text] [Related]
11. Eslicarbazepine acetate add-on for drug-resistant partial epilepsy.
Chang XC; Yuan H; Wang Y; Xu HQ; Hong WK; Zheng RY
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD008907. PubMed ID: 29067682
[TBL] [Abstract][Full Text] [Related]
12. Eslicarbazepine acetate as adjunctive therapy in clinical practice: ESLADOBA study.
Chaves J; Breia P; Pimentel J; Pelejão R; Carvalho M; Mateus P; Grebe H; Mestre A; Fernandes H; Sousa R; Gala A
Acta Neurol Scand; 2017 Nov; 136(5):407-413. PubMed ID: 28181220
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study.
Jacobson MP; Pazdera L; Bhatia P; Grinnell T; Cheng H; Blum D;
BMC Neurol; 2015 Mar; 15():46. PubMed ID: 25880756
[TBL] [Abstract][Full Text] [Related]
14. Eslicarbazepine acetate as monotherapy in clinical practice: Outcomes from Euro-Esli.
Holtkamp M; Delanty N; Sales F; Serratosa J; McMurray R; Villanueva V
Acta Neurol Scand; 2019 Jan; 139(1):49-63. PubMed ID: 30176048
[TBL] [Abstract][Full Text] [Related]
15. Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.
Elger C; Koepp M; Trinka E; Villanueva V; Chaves J; Ben-Menachen E; Kowacs PA; Gil-Nagel A; Moreira J; Gama H; Rocha JF; Soares-da-Silva P
CNS Neurosci Ther; 2017 Dec; 23(12):961-972. PubMed ID: 29030894
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of eslicarbazepine acetate monotherapy for focal-onset seizures: A multicenter audit.
Giráldez BG; Garamendi-Ruiz I; Zurita J; García A; Querol R; Campos D; Cabeza-Alvarez C; Serrano P; López-González FJ; Molins A; Serratosa JM
Acta Neurol Scand; 2019 Dec; 140(6):422-428. PubMed ID: 31498422
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of eslicarbazepine-acetate in elderly patients with focal epilepsy: Case series.
Gómez-Ibáñez A; Serratosa JM; Guillamón E; Garcés M; Giráldez BG; Toledo M; Salas-Puig J; López-González FJ; Rodríguez-Uranga J; Castillo A; Mauri JA; Camacho JL; López-Gomáriz E; Giner P; Torres N; Palau J; Molins A; Villanueva V
Seizure; 2017 May; 48():53-56. PubMed ID: 28419947
[TBL] [Abstract][Full Text] [Related]
18. EARLY-ESLI study: Long-term experience with eslicarbazepine acetate after first monotherapy failure.
Villanueva V; Bermejo P; Montoya J; Toledo M; Gómez-Ibáñez A; Garcés M; Vilella L; López-González FJ; Rodriguez-Osorio X; Campos D; Martínez P; Giner P; Zurita J; Rodríguez-Uranga J; Ojeda J; Mauri JA; Camacho JL; Ruiz-Giménez J; Poza JJ; Massot-Tarrús A; Galiano ML; Bonet M
Acta Neurol Scand; 2017 Sep; 136(3):254-264. PubMed ID: 27935017
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study.
Hufnagel A; Ben-Menachem E; Gabbai AA; Falcão A; Almeida L; Soares-da-Silva P
Epilepsy Res; 2013 Feb; 103(2-3):262-9. PubMed ID: 22871333
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies.
Gil-Nagel A; Elger C; Ben-Menachem E; Halász P; Lopes-Lima J; Gabbai AA; Nunes T; Falcão A; Almeida L; da-Silva PS
Epilepsia; 2013 Jan; 54(1):98-107. PubMed ID: 22882018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
